Literature DB >> 17675080

Effects of atrial fibrillation substrate and spatiotemporal organization on atrial defibrillation thresholds.

Thomas H Everett1, Emily E Wilson, Jeffrey E Olgin.   

Abstract

BACKGROUND: We previously showed that canine models of atrial fibrillation (AF) have different substrates (either structural or electrical) that lead to differences in AF characteristics.
OBJECTIVE: The purpose of this study was to determine whether the differences in AF characteristics also would lead to differences in atrial defibrillation thresholds (ADFTs).
METHODS: Dogs were divided into five groups: control; MR-mitral regurgitation for 5 weeks; CHF-congestive heart failure for 4 weeks; RAP-rapid atrial pacing for 6 weeks; and METH-acetyl-beta-methylcholine acutely administered. A cross-sectional area of the left atrium was calculated, and AF was induced with rapid atrial pacing. Biphasic shocks with a pulse width of 3/3 ms were delivered through specially constructed shocking catheters with a surface area of 3.7 cm(2) that were placed in the right and left atria. An up-down-up protocol was used to determine the 50% ADFT threshold (ADFT(50)). A wide-bipole AF signal was digitally filtered, and a fast Fourier transform was calculated over a 2-second window every 1 second. The dominant frequency was determined, and the organization index was calculated as the ratio of the area under the dominant peak and its harmonics to the total area of the spectrum.
RESULTS: For left atrial size, the CHF and MR groups had a significantly larger atria than did control. ADFT(50) for control, MR, CHF, RAP, and METH groups were 160 +/- 30 V, 120 +/- 50 V, 132 +/- 20 V, 668 +/- 205 V, and 593 +/- 128 V, respectively (analysis of variance, P <.0001). Dominant frequencies were significantly higher and organization indexes significantly lower in the RAP and METH models compared with the other models.
CONCLUSION: RAP and METH canine models had a significantly higher ADFT(50) compared with the other AF models. The increase in ADFT(50) in these models corresponded with higher global dominant frequencies and lower measured organization indexes.

Entities:  

Mesh:

Year:  2007        PMID: 17675080     DOI: 10.1016/j.hrthm.2007.03.032

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  6 in total

Review 1.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

2.  A left ventricular epicardial to right ventricular endocardial dominant frequency gradient exists in human ventricular fibrillation.

Authors:  Jose Luis Torres; Bindi K Shah; Richard M Greenberg; Florin Titus Deger; Edward P Gerstenfeld
Journal:  J Interv Card Electrophysiol       Date:  2010-05-12       Impact factor: 1.900

3.  Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy.

Authors:  Christina M Ambrosi; Crystal M Ripplinger; Igor R Efimov; Vadim V Fedorov
Journal:  Heart Rhythm       Date:  2010-10-19       Impact factor: 6.343

4.  Large circular ring catheter ablation versus anatomically guided ablation of atrial fibrillation: back to the future for successful catheter ablation of atrial fibrillation?

Authors:  Hui-Nam Pak
Journal:  Korean Circ J       Date:  2011-08-31       Impact factor: 3.243

5.  Does additional linear ablation after circumferential pulmonary vein isolation improve clinical outcome in patients with paroxysmal atrial fibrillation? Prospective randomised study.

Authors:  Hee-Sun Mun; Boyoung Joung; Jaemin Shim; Hye Jin Hwang; Jong Youn Kim; Moon-Hyoung Lee; Hui-Nam Pak
Journal:  Heart       Date:  2012-01-27       Impact factor: 5.994

6.  Transvenous electrical cardioversion of atrial fibrillation in horses: Horse and procedural factors correlated with success and recurrence.

Authors:  Ingrid Vernemmen; Glenn Van Steenkiste; Alexander Dufourni; Annelies Decloedt; Gunther van Loon
Journal:  J Vet Intern Med       Date:  2022-03-05       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.